Fig. 3From: Assessment of clinical immunogenicity of inotuzumab ozogamicin in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemiaDetection of anti-drug neutralizing antibodies during ALL studies. In the presence of inotuzumab ozogamicin, apoptosis of RS4;11 cells results in the reduction of signal. ALL = acute lymphoblastic leukemiaBack to article page